Insight into the October carnage from several TMT-heavy hedge funds, like Whale Rock, which saw its flagship fund plummet 11% during the month.
Shares of Orexigen Therapeutics (OREX) fell 14.68 percent to $5.81 on June 11, after the company announced that the Food and Drug Administration (FDA) decided to delay the review of its new drug
Veteran Senior Biotechnology Analyst Charles Duncan of Piper Jaffray & Co. sees platform companies as the perfect way to play a consolidating market. We've had a big run in biotech, and
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.
| Website: | www.arenapharm.com |
| Email: | IR@arenapharm.com |
| Main Phone: | +1 858 453-7200 |
| Address: | 6154 Nancy Ridge Drive |
| State: | CA |
| City / Town: | San Diego |
| Country: | US |
| Postal Code: | 92121 |
| Exchange: | NGS |
| CEO: | Amit D. Munshi |
| Employees: | 363 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Insight into the October carnage from several TMT-heavy hedge funds, like Whale Rock, which saw its flagship fund plummet 11% during the month.
Shares of Orexigen Therapeutics (OREX) fell 14.68 percent to $5.81 on June 11, after the company announced that the Food and Drug Administration (FDA) decided to delay the review of its new drug
Veteran Senior Biotechnology Analyst Charles Duncan of Piper Jaffray & Co. sees platform companies as the perfect way to play a consolidating market. We've had a big run in biotech, and
Stocks on Wall Street were up for a third consecutive session by Wednesday’s close after choppy early trading, as the Federal Reserve Chairwoman Janet Yellen reaffirmed the central
Battleground stock Arena Pharmaceuticals (ARNA) appears to have been slightly shaken when CNBC’s Jim Cramer advised viewers to sell the stock yesterday. The heavily traded stock has been
Orexigen Therapeutics, Inc. (OREX) and Takeda Pharmaceuticals are hoping that the re-submission of a New Drug Application for a weight loss drug to the U.S. Food and Drug Administration will
Wall Street was heading toward the weekend on a good note, with stocks closing higher by Friday’s closing bell. Retail sales figures were the main economic data point of the day, and while
A scant six weeks after a proxy fight with the company’s largest stockholder resulted in a a complete overturning of Vivus Inc.'s (VVUS) board and led to the installation of Tony Zook
Cult biotech stock Arena Pharmaceuticals Inc. ($ARNA) was dealt a major blow on Aug. 29 when the company’s experimental lung drug APD811 encountered a major stumbling block. The drug,
On Wednesday, the American Medical Association (AMA) officially declared obesity to be a disease. The AMA currently defines obesity as having a Body Mass Index (BMI) of over 30. At previous
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
